Oncology Peer Review On-The-Go: Inside the Advancing Inclusive Research Site Alliance for Clinical Trial Diversity

Podcast

The latest episode of CancerNetwork®’s podcast examines an initiative to diversify patient populations in oncology clinical trials and increase accessibility to these opportunities.

CancerNetwork® spoke with Quita Highsmith, vice president and Chief Diversity Officer for Genentech, and Monica Baskin, PhD, a professor of preventive medicine and associate director for Community Outreach and Engagement for the O’Neal Comprehensive Cancer Center in Birmingham, Alabama. The conversation focused on the Advancing Inclusive Research Site Alliance, which is a coalition of clinical research sites partnering with Genentech to advance representation of diverse patient populations in oncology clinical trials.

Results from clinical trials without diverse patient cohorts are rarely generalizable to the entire population, and this initiative works to educate and inform clinicians and investigators to ultimately make clinical trials more accessible and eliminate these disparities.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.